68ga-dotanoc and Bronchial-Neoplasms

Neuroendocrine tumors are slow-growing indolent tumors and often present with metastatic disease at the outset. We hereby discuss the Ga DOTANOC PET-CT findings of a 48-year-old man who has underwent lobectomy for bronchial carcinoid and developed multiple metastatic disease thereafter with event-free survival for the last 12 years.

Topics: Bronchial Neoplasms; Carcinoid Tumor; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals

Malignant tumors account for most sources of ectopic ACTH Cushing syndrome (EA-CS). Early localization of the source and complete removal can be curative and also prevent metastasis. Diagnostic CT is known to perform better than PET/CT (low dose) in characterizing lung pathologies. However, bronchial carcinoids, a common source of EA-CS, may be difficult to detect on chest CT scan especially when it is small and located close to the hilar region. We present a case of EA-CS due to bronchial carcinoid, which was easily seen on Ga DOTANOC PET/CT after a diagnostic chest CT was reported as normal.

Topics: ACTH Syndrome, Ectopic; Bronchial Neoplasms; Carcinoid Tumor; Cushing Syndrome; Female; Humans; Middle Aged; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals

Conventional imaging techniques [computed tomography (CT), ultrasound, magnetic resonance] and somatostatin receptor scintigraphy are often insufficient to make a conclusive diagnosis of bronchial carcinoid (BC). PET is commonly used for the assessment of lung cancer but 18F-fluorodeoxyglucose, the most frequently used PET tracer, presents a low sensitivity for the detection of neuroendocrine tumours (NETs). New PET radiopharmaceuticals such as 68Ga-DOTA peptides, which directly bind to somatostatin receptors and are usually expressed on NET cell surfaces, have been reported to be superior to both morphological and somatostatin receptor scintigraphy imaging for gastroenteropancreatic NETs. However, their role in BC has never been evaluated. Our aim is to evaluate the role of 68Ga-DOTA-NOC (68Ga-labelled [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-1-Nal3-octreotide) PET for the assessment of BC patients.. Ten patients with pathologically proven well-differentiated BC and one patient with highly suggestive CT images for BC were studied by 68Ga-DOTA-NOC PET/CT. PET findings were compared with clinical follow-up, pathology and contrast-enhanced CT findings.. 68Ga-DOTA-NOC PET/CT detected at least one lesion in nine of 11 patients and was negative in two. PET/CT and contrast-enhanced CT were discordant in eight of 11 patients, whereas in only three patients both provided similar results. PET/CT detected a higher number of lesions in five patients and excluded malignancy at sites considered positive on CT in three of 11; follow-up confirmed PET/CT findings in all patients. In PET/CT-positive patients, the mean maximal standardized uptake value was 25.9 [4.4-60.5]. On a clinical basis, PET/CT provided additional information in nine of 11 patients leading to the changes in the clinical management of three of nine patients.. PET/CT with Ga-DOTA-NOC was useful in BC patients because it led to a better evaluation of the extent of the disease.

Topics: Aged; Aged, 80 and over; Autoradiography; Bronchial Neoplasms; Carcinoid Tumor; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed

Topics: Aged; Aged, 80 and over; Autoradiography; Bronchial Neoplasms; Carcinoid Tumor; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed